-
2
-
-
0028792184
-
In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency
-
Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995;1:1284-90
-
(1995)
Nat Med
, vol.1
, pp. 1284-1290
-
-
Chun, T.W.1
Finzi, D.2
Margolick, J.3
-
3
-
-
14444273439
-
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
-
Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300
-
(1997)
Science
, vol.278
, pp. 1295-1300
-
-
Finzi, D.1
Hermankova, M.2
Pierson, T.3
-
4
-
-
78549235738
-
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication
-
Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010;24: 2803-8
-
(2010)
AIDS
, vol.24
, pp. 2803-2808
-
-
Chun, T.W.1
Justement, J.S.2
Murray, D.3
-
5
-
-
53849134844
-
Cellular reservoirs of HIV-1 and their role in viral persistence
-
Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008;6:388-400
-
(2008)
Curr HIV Res
, vol.6
, pp. 388-400
-
-
Alexaki, A.1
Liu, Y.2
Wigdahl, B.3
-
6
-
-
77950531446
-
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs
-
Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010;16:446-51
-
(2010)
Nat Med
, vol.16
, pp. 446-451
-
-
Carter, C.C.1
Onafuwa-Nuga, A.2
McNamara, L.A.3
-
7
-
-
60549090253
-
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation
-
Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360: 692-8
-
(2009)
N Engl J Med
, vol.360
, pp. 692-698
-
-
Hutter, G.1
Nowak, D.2
Mossner, M.3
-
8
-
-
84878503062
-
Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient
-
Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013;9:e1003347
-
(2013)
PLoS Pathog
, vol.9
-
-
Yukl, S.A.1
Boritz, E.2
Busch, M.3
-
9
-
-
84877278315
-
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation
-
Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207: 1694-702
-
(2013)
J Infect Dis
, vol.207
, pp. 1694-1702
-
-
Henrich, T.J.1
Hu, Z.2
Li, J.Z.3
-
11
-
-
84895487305
-
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV
-
Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-10
-
(2014)
N Engl J Med
, vol.370
, pp. 901-910
-
-
Tebas, P.1
Stein, D.2
Tang, W.W.3
-
12
-
-
78650735673
-
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
-
Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28:839-47
-
(2010)
Nat Biotechnol
, vol.28
, pp. 839-847
-
-
Holt, N.1
Wang, J.2
Kim, K.3
-
13
-
-
84873734105
-
RNA-guided human genome engineering via Cas9
-
Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823-6
-
(2013)
Science
, vol.339
, pp. 823-826
-
-
Mali, P.1
Yang, L.2
Esvelt, K.M.3
-
14
-
-
84883305437
-
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
-
Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013;3:2510
-
(2013)
Sci Rep
, vol.3
, pp. 2510
-
-
Ebina, H.1
Misawa, N.2
Kanemura, Y.3
Koyanagi, Y.4
-
15
-
-
84878459431
-
Reactivation of latent HIV by histone deacetylase inhibitors
-
Shirakawa K, Chavez L, Hakre S, et al. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013;21:277-85
-
(2013)
Trends Microbiol
, vol.21
, pp. 277-285
-
-
Shirakawa, K.1
Chavez, L.2
Hakre, S.3
-
16
-
-
84864203255
-
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
-
Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-5
-
(2012)
Nature
, vol.487
, pp. 482-485
-
-
Archin, N.M.1
Liberty, A.L.2
Kashuba, A.D.3
-
17
-
-
84863337769
-
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation
-
Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36:491-501
-
(2012)
Immunity
, vol.36
, pp. 491-501
-
-
Shan, L.1
Deng, K.2
Shroff, N.S.3
-
18
-
-
84878981012
-
Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs
-
Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013;381:2109-17
-
(2013)
Lancet
, vol.381
, pp. 2109-2117
-
-
Katlama, C.1
Deeks, S.G.2
Autran, B.3
-
19
-
-
13744259064
-
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART
-
Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005;115:128-37
-
(2005)
J Clin Invest
, vol.115
, pp. 128-137
-
-
Wang, F.X.1
Xu, Y.2
Sullivan, J.3
-
20
-
-
84879302206
-
Interleukin-7 promotes HIV persistence during antiretroviral therapy
-
Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013;121:4321-9
-
(2013)
Blood
, vol.121
, pp. 4321-4329
-
-
Vandergeeten, C.1
Fromentin, R.2
Dafonseca, S.3
-
21
-
-
77954685640
-
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs
-
Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 2010;6:e1000803
-
(2010)
PLoS Pathog
, vol.6
-
-
Berger, E.A.1
Pastan, I.2
-
23
-
-
79955468799
-
Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control
-
Hersperger AR, Migueles SA, Betts MR, Connors M. Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS 2011;6:169-73
-
(2011)
Curr Opin HIV AIDS
, vol.6
, pp. 169-173
-
-
Hersperger, A.R.1
Migueles, S.A.2
Betts, M.R.3
Connors, M.4
-
24
-
-
79952072932
-
Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART
-
Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011;7:e1001300
-
(2011)
PLoS Pathog
, vol.7
-
-
Graf, E.H.1
Mexas, A.M.2
Yu, J.J.3
-
25
-
-
84881319698
-
Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance
-
Graf EH, Pace MJ, Peterson BA, et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS One 2013;8: e71879
-
(2013)
PLoS One
, vol.8
-
-
Graf, E.H.1
Pace, M.J.2
Peterson, B.A.3
-
26
-
-
84885669019
-
Immune clearance of highly pathogenic SIV infection
-
Hansen SG, Piatak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013;502:100-4
-
(2013)
Nature
, vol.502
, pp. 100-104
-
-
Hansen, S.G.1
Piatak Jr., M.2
Ventura, A.B.3
-
27
-
-
84877949177
-
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire
-
Casazza JP, Bowman KA, Adzaku S, et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis 2013;207:1829-40
-
(2013)
J Infect Dis
, vol.207
, pp. 1829-1840
-
-
Casazza, J.P.1
Bowman, K.A.2
Adzaku, S.3
-
28
-
-
84872037286
-
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication
-
Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013;5:166ra162
-
(2013)
Sci Transl Med
, vol.5
-
-
Garcia, F.1
Climent, N.2
Guardo, A.C.3
-
29
-
-
32544459770
-
Restoring function in exhausted CD8 T cells during chronic viral infection
-
Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7
-
(2006)
Nature
, vol.439
, pp. 682-687
-
-
Barber, D.L.1
Wherry, E.J.2
Masopust, D.3
-
30
-
-
62249172189
-
Enhancing SIV-specific immunity in vivo by PD-1 blockade
-
Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009;458:206-10
-
(2009)
Nature
, vol.458
, pp. 206-210
-
-
Velu, V.1
Titanji, K.2
Zhu, B.3
-
32
-
-
84879759020
-
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
-
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44
-
(2013)
N Engl J Med
, vol.369
, pp. 134-144
-
-
Hamid, O.1
Robert, C.2
Daud, A.3
-
33
-
-
82555187124
-
Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication
-
Pallikkuth S, Rogers K, Villinger F, et al. Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine 2011;29:9229-38
-
(2011)
Vaccine
, vol.29
, pp. 9229-9238
-
-
Pallikkuth, S.1
Rogers, K.2
Villinger, F.3
-
34
-
-
84862889768
-
Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes
-
Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer 2011;2:378-82
-
(2011)
J Cancer
, vol.2
, pp. 378-382
-
-
Casucci, M.1
Bondanza, A.2
-
35
-
-
84860718270
-
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
-
Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra153
-
(2012)
Sci Transl Med
, vol.4
-
-
Scholler, J.1
Brady, T.L.2
Binder-Scholl, G.3
-
36
-
-
84887028999
-
Absence of detectable HIV-1 viremia after treatment cessation in an infant
-
Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828-35
-
(2013)
N Engl J Med
, vol.369
, pp. 1828-1835
-
-
Persaud, D.1
Gay, H.2
Ziemniak, C.3
-
37
-
-
84865717158
-
HIV-1 control after transient antiretroviral treatment initiated in primary infection: Role of patient characteristics and effect of therapy
-
Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012;17:1001-9
-
(2012)
Antivir Ther
, vol.17
, pp. 1001-1009
-
-
Goujard, C.1
Girault, I.2
Rouzioux, C.3
-
38
-
-
84875985311
-
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study
-
Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9:e1003211
-
(2013)
PLoS Pathog
, vol.9
-
-
Saez-Cirion, A.1
Bacchus, C.2
Hocqueloux, L.3
-
39
-
-
84872452352
-
Short-course antiretroviral therapy in primary HIV infection
-
Investigators ST
-
Investigators ST, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368:207-17
-
(2013)
N Engl J Med
, vol.368
, pp. 207-217
-
-
Fidler, S.1
Porter, K.2
-
40
-
-
84886401909
-
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
-
Stohr W, Fidler S, McClure M, et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE 2013;8:e78287
-
(2013)
PLoS ONE
, vol.8
-
-
Stohr, W.1
Fidler, S.2
McClure, M.3
-
41
-
-
20244376915
-
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1
-
Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005;191: 1410-18
-
(2005)
J Infect Dis
, vol.191
, pp. 1410-1418
-
-
Strain, M.C.1
Little, S.J.2
Daar, E.S.3
-
42
-
-
84885058930
-
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size
-
Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208: 1202-11
-
(2013)
J Infect Dis
, vol.208
, pp. 1202-1211
-
-
Jain, V.1
Hartogensis, W.2
Bacchetti, P.3
-
43
-
-
0034724371
-
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
-
Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-7
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 3382-3387
-
-
Oxenius, A.1
Price, D.A.2
Easterbrook, P.J.3
-
44
-
-
84873472629
-
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies
-
Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013;9:e1003174
-
(2013)
PLoS Pathog
, vol.9
-
-
Eriksson, S.1
Graf, E.H.2
Dahl, V.3
-
45
-
-
84878482232
-
Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay
-
Laird GM, Eisele EE, Rabi SA, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013;9:e1003398
-
(2013)
PLoS Pathog
, vol.9
-
-
Laird, G.M.1
Eisele, E.E.2
Rabi, S.A.3
-
46
-
-
84873421734
-
Quantitation of integrated proviral DNA in viral reservoirs
-
Graf EH, O'Doherty U. Quantitation of integrated proviral DNA in viral reservoirs. Curr Opin HIV AIDS 2013;8:100-5
-
(2013)
Curr Opin HIV AIDS
, vol.8
, pp. 100-105
-
-
Graf, E.H.1
O'doherty, U.2
-
47
-
-
84886769508
-
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure
-
Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155: 540-51
-
(2013)
Cell
, vol.155
, pp. 540-551
-
-
Ho, Y.C.1
Shan, L.2
Hosmane, N.N.3
-
48
-
-
84871797372
-
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration
-
Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013;207:213-22
-
(2013)
J Infect Dis
, vol.207
, pp. 213-222
-
-
Azzoni, L.1
Foulkes, A.S.2
Papasavvas, E.3
-
49
-
-
33751515147
-
Strategies for Management of Antiretroviral Therapy Study G. CD4+ count-guided interruption of antiretroviral treatment
-
El-Sadr WM, Lundgren J, Neaton JD, Gordin F, et al. Strategies for Management of Antiretroviral Therapy Study G. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355: 2283-96
-
(2006)
N Engl J Med
, vol.355
, pp. 2283-2296
-
-
El-Sadr, W.M.1
Lundgren, J.2
Neaton, J.D.3
Gordin, F.4
-
50
-
-
34548222243
-
Risk of cancers during interrupted antiretroviral therapy in the SMART study
-
Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007;21:1957-63
-
(2007)
AIDS
, vol.21
, pp. 1957-1963
-
-
Silverberg, M.J.1
Neuhaus, J.2
Bower, M.3
-
52
-
-
67649666969
-
CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART
-
Maggiolo F, Airoldi M, Callegaro A, et al. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 2009;23:799-807
-
(2009)
AIDS
, vol.23
, pp. 799-807
-
-
Maggiolo, F.1
Airoldi, M.2
Callegaro, A.3
-
53
-
-
33745102005
-
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/-interleukin 2: Results of ACTG A5102
-
Henry K, Katzenstein D, Cherng DW, et al. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/-interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr 2006;42:140-8
-
(2006)
J Acquir Immune Defic Syndr
, vol.42
, pp. 140-148
-
-
Henry, K.1
Katzenstein, D.2
Cherng, D.W.3
-
54
-
-
33746479812
-
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial
-
Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006;368:459-65
-
(2006)
Lancet
, vol.368
, pp. 459-465
-
-
Ananworanich, J.1
Gayet-Ageron, A.2
Le Braz, M.3
-
55
-
-
0037324326
-
Enhanced risk of HIV sexual transmission during structured treatment interruption
-
Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruption. Sex Transm Infect 2003;79:74
-
(2003)
Sex Transm Infect
, vol.79
, pp. 74
-
-
Teicher, E.1
Casagrande, T.2
Vittecoq, D.3
-
56
-
-
55949084601
-
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection
-
Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203
-
(2008)
PLoS Med
, vol.5
-
-
Kuller, L.H.1
Tracy, R.2
Belloso, W.3
-
57
-
-
79952335046
-
Plasma levels of soluble CD14 independently predict mortality in HIV infection
-
Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203: 780-90
-
(2011)
J Infect Dis
, vol.203
, pp. 780-790
-
-
Sandler, N.G.1
Wand, H.2
Roque, A.3
-
58
-
-
70349434886
-
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection
-
Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009;200: 973-83
-
(2009)
J Infect Dis
, vol.200
, pp. 973-983
-
-
Rodger, A.J.1
Fox, Z.2
Lundgren, J.D.3
-
59
-
-
67049172548
-
HIV increases markers of cardiovascular risk: Results from a randomized, treatment interruption trial
-
Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009;23:929-39
-
(2009)
AIDS
, vol.23
, pp. 929-939
-
-
Calmy, A.1
Gayet-Ageron, A.2
Montecucco, F.3
-
60
-
-
79952116429
-
A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir
-
Piketty C, Weiss L, Assoumou L, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol 2010;82:1819-28
-
(2010)
J Med Virol
, vol.82
, pp. 1819-1828
-
-
Piketty, C.1
Weiss, L.2
Assoumou, L.3
-
61
-
-
84866735012
-
Continuous versus intermittent treatment strategies during primary HIV-1 infection: The randomized ANRS INTERPRIM Trial
-
Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS 2012;26:1895-905
-
(2012)
AIDS
, vol.26
, pp. 1895-1905
-
-
Goujard, C.1
Emilie, D.2
Roussillon, C.3
|